2022
DOI: 10.1111/dth.15303
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of omalizumab in Chinese patients with anti‐histamine refractory chronic spontaneous urticaria

Abstract: Chronic spontaneous urticaria (CSU) is characterized by the spontaneous development of wheals, itching, and/or angioedema, for ≥6 weeks. In China, non‐sedating H1‐antihistamines (H1AH) are the recommended first‐line treatment, with escalation up to 4× the standard dose in symptomatic patients to achieve control. Treatment options for Chinese patients who remain symptomatic on H1AH treatment are limited. This 20‐week randomized, double blind, placebo‐controlled, parallel‐group study investigated the efficacy an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

3
28
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 21 publications
(32 citation statements)
references
References 13 publications
3
28
1
Order By: Relevance
“…The effect of omalizumab was dose dependent [ 32 ]. A similar efficacy was observed in 418 Chinese adult patients ( p < 0.001) [ 36 ].…”
Section: Resultssupporting
confidence: 74%
See 4 more Smart Citations
“…The effect of omalizumab was dose dependent [ 32 ]. A similar efficacy was observed in 418 Chinese adult patients ( p < 0.001) [ 36 ].…”
Section: Resultssupporting
confidence: 74%
“…Twenty-nine articles and trials with preliminary results met the eligibility criteria (overall, 3110 patients) [ 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 ]. They will be discussed in the following paragraphs.…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations